ESSIG STUART 4

What Happened
Stuart Essig, President, CEO and a director of Integra LifeSciences Holdings Corp. (IART), was granted equity awards on 2026-06-01 consisting of 705,468 stock options and 365,297 restricted stock units (RSUs) — 1,070,765 awards in total. The reported acquisition price for these awards is $0 (these are compensation grants, not open-market purchases). The awards were made under the company's equity incentive plan and vest as to one-third on the first anniversary of 5/1/2026, with the remainder vesting monthly over the following 24 months, subject to continued service.

Key Details

• Transaction date: 2026-06-01; Filing date: 2026-06-03 (filed two days after the grant).
• Award breakdown: 705,468 stock options; 365,297 RSUs (total 1,070,765). Acquisition price reported as $0.
• Vesting: 1/3 vest on 5/1/2027, remainder monthly over the next 24 months (subject to continued service).
• Footnotes: Options consist of 482,976 granted under the executive employment agreement and 222,492 discretionary by the Compensation Committee. RSUs consist of 255,265 under the employment agreement and 110,032 discretionary. All awards are granted under the company’s Equity Incentive Plan.
• Shares owned after transaction: not specified in the filing.
• No immediate sale or exercise reported (these are grants/awards).

Context
RSUs represent a contingent right to receive one share per unit when vested; stock options give the right to purchase shares subject to their exercise terms. These awards are standard compensation for executives and are not open-market purchases or sales, so they reflect compensation decisions rather than direct buy/sell bets by the insider. The filing appears timely (filed within two business days of the grant).